Eli Lilly's obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly medication. This comes after Zepbound's FDA approval for a secondary use, allowing Medicare coverage. Insurers may still opt not to cover the drug despite the new guidance.